novel agents in elderly cll patients: should the approach be different?
Published 4 years ago • 494 plays • Length 20:21Download video MP4
Download video MP3
Similar videos
-
24:17
combination of novel agents in cll: is this the final answer?
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
16:24
chemotherapy vs novel agents in young cll patients: is there still a role for chemo?
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
22:47
the sequencing of novel agents: does it matter?
-
13:19
ighv and tp53 sequencing: clinical utility in chronic lymphocytic leukemia (cll)
-
10:30
leukemia patient story: my 1st symptoms for cll | stephen's story (1/5) | the patient story
-
36:26
fact or fiction? cll causes and symptoms
-
21:19
cll: sequencing monotherapy vs. combination therapy
-
1:01
cll resistance mechanisms in the era of novel agents
-
27:18
novel treatment options in cll
-
12:34
debate: is it appropriate to treat patients with cll earlier in the era of novel agents? - no
-
18:49
use of novel prognostic markers in practice for cll
-
14:07
novel agents in the pipeline for cll & lymphoma
-
21:05
cll: optimal approaches for patients with deletion 17p
-
1:00
how to treat elderly cll patients in the light of novel therapies
-
1:55
novel agents in cll: the importance of affordability
-
23:41
novel therapeutic approaches in cll
-
0:52
the differences in treating older versus younger cll patients
-
23:28
richter’s syndrome: what are the options?
-
1:45:28
chronic lymphocytic leukaemia (cll) education presentation